Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033
Expert Review of Pharmacoeconomics & Outcomes Research · 16.03.2026 · 26 (3) · 429-441
DOI: 10.1080/14737167.2026.2634755 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2026-03. Verfasst von Gittan Blezer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lumanity, Utrecht, Netherlands. Hauptthemen laut MEDLINE: Immunotherapy, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 92 Literaturangaben. Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc., Rahway, NJ, USA.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lumanity, Utrecht, Netherlands.
- Lumanity, Sheffield, UK.
- MSD, Prague, Czech Republic.
- Merck & Co. Inc., Rahway, NJ, USA.
- Value & Implementation Outcomes Research, MSD Sharp & Dohme GmbH, Munich, Germany.
- Merck Canada Inc., Kirkland, QC, Canada.
Förderung
- Merck Sharp & Dohme LLC
- Merck & Co., Inc., Rahway, NJ, USA
Zitieren
APA
Blezer, G., Patterson, K., MIčoch, T., Alahakoon, J., Lai, Y., Khurana, V., & Aguiar-Ibáñez, R. (2026). Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033. Expert Review of Pharmacoeconomics & Outcomes Research, 26(3), 429-441. https://doi.org/10.1080/14737167.2026.2634755
Vancouver
Blezer G, Patterson K, MIčoch T, Alahakoon J, Lai Y, Khurana V, et al. Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(3):429-441. doi:10.1080/14737167.2026.2634755
BibTeX
@article{Blezer2026,
author = {Blezer, Gittan and Patterson, Karl and MIčoch, Tomáš and Alahakoon, Jana and Lai, Yizhen and Khurana, Vivek and Aguiar-Ibáñez, Raquel},
title = {Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {3},
pages = {429--441},
doi = {10.1080/14737167.2026.2634755}
}
EUVIMED